Researchers hunt for clues to improve cancer treatment in patients who Can't take standard chemo

NCT ID NCT06947668

First seen Mar 17, 2026 · Last updated May 16, 2026 · Updated 10 times

Summary

This study looks at 250 patients with head and neck cancers who cannot take the standard chemotherapy drug cisplatin. Researchers will analyze tumor tissue, saliva, stool, and blood samples to find biological markers that predict how well treatment with chemoradiotherapy and docetaxel works. The goal is to identify which patients benefit most and to understand treatment side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARYNX SQUAMOUS CELL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Universitätsklinikum Erlangen, Strahlenklinik

    RECRUITING

    Erlangen, Bavaria, 91054, Germany

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.